

ZEPBOUND (AUTOINJECTOR) - (2.5MG/0.5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML, 15MG/0.5ML ; Solution)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | TIRZEPATIDE | Innovator | Eli Lilly |
| Dosage | 2.5MG/0.5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML, 15MG/0.5ML ; Solution | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | ZEPBOUND™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: • 30 kg/m ² or greater (obesity) or • 27 kg/m ² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease) | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

ZEPBOUND (AUTOINJECTOR) - (2.5MG/0.5ML (2.5MG/0.5ML), 5MG/0.5ML (5MG/0.5ML), 7.5MG/0.5ML (7.5MG/0.5ML), 10MG/0.5ML (10MG/0.5ML), 12.5MG/0.5ML (12.5MG/0.5ML), 15MG/0.5ML (15MG/0.5ML); SOLUTION)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | TIRZEPATIDE | Innovator | None |
| Dosage | 2.5MG/0.5ML (2.5MG/0.5ML), 5MG/0.5ML (5MG/0.5ML), 7.5MG/0.5ML (7.5MG/0.5ML), 10MG/0.5ML (10MG/0.5ML), 12.5MG/0.5ML (12.5MG/0.5ML), 15MG/0.5ML (15MG/0.5ML); SOLUTION | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | ZEPBOUND™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: • 30 kg/m ² or greater (obesity) or • 27 kg/m ² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease) | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.